• Cyclodextrins and TRPV1/TRPA1 Pain Signaling

  2026-10-05

  The 2025 study by Nehr-Majoros and colleagues examines whether cholesterol depletion by cyclodextrin derivatives can reduce nociception driven by TRPV1 and TRPA1 without relying on conventional receptor antagonism. Its mouse, biochemical, and computational evidence supports membrane lipid organization as a potential modulator of peripheral pain and neurogenic inflammation, while leaving important questions about specificity, durability, and clinical translation.

• GPR35–KLF5 Signaling in Epithelial Repair

  2026-10-05

  The reference study identifies a tryptophan–kynurenine–kynurenic acid sensing mechanism in which GPR35 connects mucosal damage signals to KLF5-dependent epithelial repair. Its findings place PI3K–AKT–mTOR signaling, epithelial proliferation, and migration within a proposed repair circuit relevant to ulcerative colitis research, while leaving important questions about model context and clinical transferability.

• Nonivamide: From TRPV1 Biology to Translation

  2026-10-04

  Nonivamide, a capsaicin analog and TRPV1 agonist, offers translational researchers a chemical lens for studying sensory biology, inflammation, and cancer cell growth inhibition. This thought-leadership article connects supplier-reported oncology findings with a 2024 dermatitis study while distinguishing mechanistic evidence from early-stage hypotheses and outlining strategic questions for future validation.

• Ruthenium Red and Calcium Mechanotransduction

  2026-10-03

  Mechanical stress, cytoskeletal architecture, calcium transport, and autophagy intersect in a translationally important signaling problem. This evidence-led perspective examines how Ruthenium Red can serve as a broad Ca2+ transport inhibitor for testing mechanistic hypotheses while emphasizing its selectivity limits, provenance, and preclinical boundaries.

• MLN4924: From NAE Inhibition to CRL Logic

  2026-10-02

  MLN4924 is a selective NEDD8-activating enzyme inhibitor that converts neddylation biology into a measurable experimental framework. This article connects CRL4DCAF13–MeCP2 substrate control in oocytes with rigorous assay design for cancer biology research, while clarifying what pharmacological pathway inhibition can and cannot prove.

• Cytoskeleton-Dependent Autophagy Under Mechanical Stress

  2026-10-01

  The reference study shows that compressive-force-induced autophagy depends primarily on cytoskeletal microfilaments, while microtubules make a supporting contribution. By combining cytoskeletal polymerization perturbations with fluorescence imaging and western blotting, the work provides a mechanistic framework for studying how mechanical inputs become autophagy signals.

• TRPV1 Modulation in Metastatic Breast Cancer Immunity

  2026-10-01

  The reference study shows that pharmacological TRPV1 modulation produces sharply different cytokine responses in immune cells from healthy and metastatic breast carcinoma-bearing mice. Its organ-specific 4T1 model and unexpected AMG9810 behavior highlight why receptor activity, tumor context, and compound-specific intrinsic actions must be separated when evaluating TRPV1-based interventions.

• TBXA2R–ERM Signaling in TNBC Metastasis

  2026-09-30

  The reference study identifies TBXA2R as an upstream activator of ezrin, radixin, and moesin in triple-negative breast cancer, linking GPCR signaling to cytoskeletal control of motility, invasion, and metastatic colonization. Its mechanistic model places Gαq/11, Gα12/13, Rho GTPases, and the kinases SLK and LOK between TBXA2R and ERM-dependent metastatic behavior.

• Dinaciclib for Cell Cycle and Boundary Research

  2026-09-30

  Dinaciclib (SCH727965) supports integrated cell-cycle, apoptosis, and quantitative imaging workflows rather than serving only as a viability reagent. This guide translates new Drosophila boundary biology into practical assay designs while emphasizing formulation control, orthogonal readouts, and careful interpretation of cross-domain results.

• AMPK–SQSTM1 Feedback Under Metabolic Stress

  2026-09-29

  The 2024 Autophagy study identifies a double-positive feedback loop between AMPK and SQSTM1/p62 that coordinates lysosomal stress adaptation with KEAP1 degradation and NRF2 activation. Its mechanistic model links metabolic stress, lysosomal deacidification, TAK1-dependent p62 phosphorylation, and AXIN–STK11–AMPK assembly, offering a framework for interpreting antioxidant adaptation in STK11- and KEAP1-altered lung cancer.

• Cyanine 5-dCTP in Precision DNA Synthesis

  2026-09-29

  Cyanine 5-dCTP connects enzymatic DNA synthesis with direct fluorescent readout. By pairing Cy5-dCTP with structured primer interfaces such as tetrahedral DNA nanostructures, translational researchers can investigate synthesis fidelity, enzyme accessibility, and sequence detection without overstating evidence that remains preclinical and workflow-dependent.

• SB-3CT: A Causal Probe of MMP9–PNN Biology

  2026-09-28

  The Adamtsl3–MMP9–perineuronal-net axis offers a compelling model for studying extracellular-matrix control of cortical plasticity. This thought-leadership article explains how SB-3CT can help translational researchers move from correlation to causal testing while preserving the distinction between MMP-9 biology, MMP-2 activity, preclinical evidence, and clinical relevance.

• Prevotella copri Depletes IPA to Promote Breast Cancer

  2026-09-28

  A 2024 study links gut enrichment of Prevotella copri with lower host indole-3-pyruvic acid (IPA) and faster breast tumor growth in mouse models. Its proposed mechanism connects microbial tryptophan consumption to UHRF1-associated suppression of AMPK signaling, identifying a testable microbiome–metabolite pathway rather than establishing a clinical cause of breast cancer progression.

• Carboplatin Resistance: Better TNBC Assay Design

  2026-09-27

  Carboplatin response in triple-negative breast cancer depends on more than drug exposure: stem-like cell state and DNA repair can shape apparent resistance. This guide turns the IGF2BP3–FZD1/7 findings into practical assay-design decisions for preclinical oncology research.

• Cy3 Goat Anti-Mouse IgG (H+L) Antibody Guide

  2026-09-26

  Cy3 Goat Anti-Mouse IgG (H+L) Antibody is a fluorescent mouse IgG detection antibody for visualizing mouse primary antibodies in immunofluorescence, flow cytometry, and western blotting. Use it only after confirming primary-antibody compatibility and assay controls; it is for research use only, not diagnostic or medical use, and its preservative makes it unsuitable to assume compatibility with live-cell functional assays.

8110 records 1/541 page Next 12345 下5页 Last page